{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T02:26:53Z","timestamp":1760149613472,"version":"build-2065373602"},"reference-count":77,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Left ventricular diastolic dysfunction (DD) is a subclinical cardiac abnormality in patients with type 2 diabetes mellitus (T2DM) that can progress to heart failure (HF) and increase cardiovascular risk. This prospective study evaluated the DD in T2DM patients without atherosclerotic cardiovascular disease after one year of incretin-based drugs added to standard treatment. Of the 138 enrolled patients (49.30% male, mean age 57.86 \u00b1 8.82, mean T2DM history 5 years), 71 were started on dipeptidyl peptidase-4 inhibitor sitagliptin\/saxagliptin, 21 on glucagon-like peptide-1 receptor agonist exenatide, and 46 formed the control group (metformin and sulphonylurea\/acarbose). At baseline, 71 patients had grade 1 DD, another 12 had grade 2 and 3 DD, and 15 had indeterminate DD. After one year, DD was evidenced in 50 cases. Diastolic function improved in 9 cases, and 27 patients went from grade 1 to indeterminate DD. The active group benefited more, especially patients treated with exenatide; their metabolic and inflammation profiles also improved the most. An in-depth analysis of echocardiographic parameters and paraclinical results in the context of literature data justifies the conclusion that early assessment of diastolic function in T2DM patients is necessary and the benefits of affordable incretin-based treatment may extend to subclinical cardiovascular manifestations such as DD.<\/jats:p>","DOI":"10.3390\/diagnostics13172817","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T11:33:25Z","timestamp":1693481605000},"page":"2817","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7721-554X","authenticated-orcid":false,"given":"Elena-Daniela","family":"Grigorescu","sequence":"first","affiliation":[{"name":"Unit of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9012-5901","authenticated-orcid":false,"given":"Cristina-Mihaela","family":"L\u0103c\u0103tu\u0219u","sequence":"additional","affiliation":[{"name":"Unit of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"},{"name":"Clinical Center of Diabetes, Nutrition and Metabolic Diseases, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9465-1503","authenticated-orcid":false,"given":"Mariana","family":"Floria","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"},{"name":"Medical Clinic, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6993-5491","authenticated-orcid":false,"given":"Georgiana-Diana","family":"Cazac","sequence":"additional","affiliation":[{"name":"Unit of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"},{"name":"Clinical Center of Diabetes, Nutrition and Metabolic Diseases, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Onofriescu","sequence":"additional","affiliation":[{"name":"Unit of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"},{"name":"Clinical Center of Diabetes, Nutrition and Metabolic Diseases, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia-Amira","family":"Sauciuc","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0043-9051","authenticated-orcid":false,"given":"Alexandr","family":"Ceasovschih","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"},{"name":"Medical Clinic, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioana","family":"Cre\u021bu","sequence":"additional","affiliation":[{"name":"Cre\u021bu R. Ioana PFA, 1 M\u0103rului, 707020 Aroneanu, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0413-026X","authenticated-orcid":false,"given":"Bogdan-Mircea","family":"Mihai","sequence":"additional","affiliation":[{"name":"Unit of Diabetes, Nutrition and Metabolic Diseases, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"},{"name":"Clinical Center of Diabetes, Nutrition and Metabolic Diseases, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren\u021biu","family":"\u0218orodoc","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, \u201cGrigore T. Popa\u201d University of Medicine and Pharmacy, 700115 Ia\u0219i, Romania"},{"name":"Medical Clinic, \u201cSf. Spiridon\u201d County Clinical Emergency Hospital, 700111 Ia\u0219i, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"ref_1","unstructured":"International Diabetes Federation (2021). IDF Diabetes Atlas, International Diabetes Federation. [10th ed.]. Available online: https:\/\/diabetesatlas.org\/idfawp\/resource-files\/2021\/07\/IDF_Atlas_10th_Edition_2021.pdf."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"(2023). The Lancet Diabetes: A defining disease of the 21st century. Lancet, 401, 2087.","DOI":"10.1016\/S0140-6736(23)01296-5"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0140-6736(23)00914-5","article-title":"Interventions to address global inequity in diabetes: International progress","volume":"402","author":"Walker","year":"2023","journal-title":"Lancet"},{"key":"ref_4","unstructured":"Lobstein, T., Jackson-Leach, R., Powis, J., Brindsen, H., and Gray, M. (2023). World Obesity Atlas, World Obesity Federation. Available online: https:\/\/policycommons.net\/artifacts\/3454894\/untitled\/4255209\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00125-022-05787-2","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"65","author":"Davies","year":"2022","journal-title":"Diabetologia"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e15740","DOI":"10.14814\/phy2.15740","article-title":"Type 1 diabetes management in a competitive athlete: A five-year case report","volume":"11","author":"Cannataro","year":"2023","journal-title":"Physiol. Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"10429","DOI":"10.3390\/ijerph191610429","article-title":"Ketogenic Diet Benefits to Weight Loss, Glycemic Control, and Lipid Profiles in Overweight Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trails","volume":"19","author":"Zhou","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/2211536608666181126093903","article-title":"Ketogenic diet acts on body remodeling and MicroRNAs expression profile","volume":"8","author":"Cannataro","year":"2019","journal-title":"MicroRNA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.3390\/nu15153368","article-title":"The Ketogenic Diet and Cardiovascular Diseases","volume":"15","author":"Kowalcze","year":"2023","journal-title":"Nutrients"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007\u20132017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/diagnostics9030121","article-title":"Left Ventricular Diastolic Dysfunction in Type 2 Diabetes-Progress and Perspectives","volume":"9","author":"Grigorescu","year":"2019","journal-title":"Diagnostics"},{"key":"ref_12","first-page":"OC20-2","article-title":"Study on Diastolic Dysfunction in Newly Diagnosed Type 2 Diabetes Mellitus and its Correlation with Glycosylated Haemoglobin (HbA1C)","volume":"9","author":"Chaudhary","year":"2015","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","article-title":"Cardiovascular phenotype in HFpEF patients with or without diabetes: A RELAX trial ancillary study","volume":"64","author":"Lindman","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1758-5996-6-103","article-title":"Left ventricular diastolic function in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor\u2014A pilot study","volume":"6","author":"Nogueira","year":"2014","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_15","first-page":"249","article-title":"Diastolic Dysfunction in Diabetes Mellitus","volume":"3","author":"Dikshit","year":"2013","journal-title":"Natl. J. Med. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jacc.2013.10.063","article-title":"Pre-clinical diastolic dysfunction","volume":"63","author":"Wan","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jacc.2009.12.003","article-title":"The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study","volume":"55","author":"From","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2337\/dc15-1585","article-title":"The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the \u03b2-Cell-Centric Classification Schema","volume":"39","author":"Schwartz","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00125-021-05637-7","article-title":"Metabolic, structural and biochemical changes in diabetes and the development of heart failure","volume":"65","author":"Ho","year":"2022","journal-title":"Diabetologia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"603247","DOI":"10.3389\/fphys.2020.603247","article-title":"The Impact of Antidiabetic Therapies on Diastolic Dysfunction and Diabetic Cardiomyopathy","volume":"11","author":"Gopal","year":"2020","journal-title":"Front. Physiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12933-020-0987-x","article-title":"Effects of antidiabetic drugs on left ventricular function\/dysfunction: A systematic review and network meta-analysis","volume":"19","author":"Zhang","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10557-014-6512-2","article-title":"METformin in DIastolic dysfunction of MEtabolic syndrome (MET-DIME) trial: Rationale and study design: MET-DIME trial","volume":"28","author":"Bettencourt","year":"2014","journal-title":"Cardiovasc. Drugs. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-10-0624","article-title":"Metformin is associated with improved left ventricular diastolic function measured by tissue doppler imaging in patients with diabetes","volume":"163","author":"Andersson","year":"2010","journal-title":"Eur. J. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12933-017-0546-2","article-title":"Effect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: A subgroup analysis of the PROLOGUE study","volume":"16","author":"Yamada","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12933-015-0242-z","article-title":"Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type. 2 diabetes: Results of the. 3D trial","volume":"14","author":"Oe","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/2047487320939217","article-title":"Effects of linagliptin on left ventricular DYsfunction in patients with type. 2 DiAbetes and concentric left ventricular geometry: Results of the DYDA 2 trial","volume":"28","author":"Cioffi","year":"2020","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/dom.15006","article-title":"Empagliflozin versus sitagliptin for ameliorating intrahepatic lipid content and tissue-specific insulin sensitivity in patients with early-stage type 2 diabetes with non-alcoholic fatty liver disease: A prospective randomized study","volume":"25","author":"Hiruma","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s10741-021-10106-9","article-title":"New antidiabetic therapy and HFPEF: Light at the end of tunnel?","volume":"27","author":"Tadic","year":"2021","journal-title":"Heart Fail. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/imj.14260","article-title":"Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: A cardiac magnetic resonance study","volume":"49","author":"Cohen","year":"2019","journal-title":"Intern. Med. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12933-018-0717-9","article-title":"Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes","volume":"17","author":"Matsutani","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals with Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10557-019-06892-y","article-title":"Effect of Tofogliflozin on Systolic and Diastolic Cardiac Function in Type 2 Diabetic Patients","volume":"33","author":"Otagaki","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s12933-019-0857-6","article-title":"Effect of liraglutide on cardiac function in patients with tye 2 diabetes mellitus: Randomized placebo-controlled trial","volume":"18","author":"Bizino","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.diabres.2016.04.046","article-title":"Improved diastolic function in type 2 diabetes after a six month liraglutide treatment","volume":"118","author":"Saponaro","year":"2016","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2042018819834869","article-title":"Diabetic cardiomyopathy: Prevalence, determinants and potential treatments","volume":"10","author":"Gulsin","year":"2019","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ahj.2018.03.030","article-title":"Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristics","volume":"203","author":"Green","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10557-020-07032-7","article-title":"LEADER Trial Eligibility and Preventable Cardiovascular Events in US Adults with Diabetes: The National Health and Nutrition Examination Surveys 2007\u20132016","volume":"34","author":"Fan","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Kotlyarov, S. (2021). Diversity of Lipid Function in Atherogenesis: A Focus on Endothelial Mechanobiology. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111545"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.2337\/db09-1694","article-title":"Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4","volume":"59","author":"Arakawa","year":"2010","journal-title":"Diabetes"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/cvr\/cvz323","article-title":"Cardiovascular effects of glucagon-like peptide 1 receptor agonists: From mechanistic studies in humans to clinical outcomes","volume":"116","author":"Heuvelman","year":"2020","journal-title":"Cardiovasc. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1161\/CIRCULATIONAHA.117.028136","article-title":"Cardiovascular Actions and Clinical Outcomes with Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors","volume":"136","author":"Nauck","year":"2017","journal-title":"Circulation"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.37358\/RC.19.5.7216","article-title":"The inflammatory marker HSCRP as a predictor of increased insulin resistance in type 2 diabetics without atherosclerotic manifestations","volume":"70","author":"Grigorescu","year":"2019","journal-title":"Rev. Chim."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014State-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S140","DOI":"10.2337\/dc23-S009","article-title":"9. pharmacologic approaches to glycemic treatment: Standards of care in diabetes\u20142023","volume":"46","author":"ElSayed","year":"2022","journal-title":"Diabetes Care"},{"key":"ref_49","first-page":"161","article-title":"Evolution of exenatide as a diabetes therapeutic","volume":"9","author":"Bhavsar","year":"2013","journal-title":"Curr. Diabetes Rev."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","article-title":"Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: A case report","volume":"70","author":"Klein","year":"2023","journal-title":"Can. J. Anesth."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/dom.13266","article-title":"Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The duration-7 Randomized Study","volume":"20","author":"Guja","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_52","first-page":"66","article-title":"The Effects of Exenatide on Serum CRP Levels in Patients with Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials","volume":"27","author":"Apan","year":"2020","journal-title":"Rom. J. Diabetes Nutr. Metab. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.metabol.2012.09.004","article-title":"A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients","volume":"62","author":"Sasaki","year":"2013","journal-title":"Metabolism"},{"key":"ref_54","first-page":"212","article-title":"Prevalence of Diastolic Dysfunction in Type 2 Diabetes Mellitus","volume":"15","author":"Yadava","year":"2017","journal-title":"Kathmandu Univ. Med. J. (KUMJ)"},{"key":"ref_55","first-page":"35","article-title":"Frequency of diastolic dysfunction in asymptomatic, normotensive type 2 diabetic patients","volume":"26","author":"Randhawa","year":"2014","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"key":"ref_56","first-page":"50","article-title":"A Comparative Study of Diastolic Dysfunction by Echocardiography among Diabetic and Non-Diabetic Subjects","volume":"9","author":"Patil","year":"2020","journal-title":"J. Krishna Inst. Med. Sci. Univ."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"676862","DOI":"10.3389\/fcvm.2021.676862","article-title":"Prevalence and predictors of left ventricular diastolic dysfunction in Malaysian patients with type 2 diabetes mellitus without prior known cardiovascular disease","volume":"8","author":"Chee","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12933-014-0168-x","article-title":"Diastolic dysfunction in the diabetic continuum: Association with insulin resistance, metabolic syndrome and type 2 diabetes","volume":"14","author":"Bettencourt","year":"2015","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2337\/db15-0627","article-title":"Relationship between left ventricular structural and metabolic remodeling in type 2 diabetes","volume":"65","author":"Levelt","year":"2016","journal-title":"Diabetes"},{"key":"ref_60","first-page":"11","article-title":"Association of glycosylated haemoglobin (hba1c) level with left ventricular diastolic dysfunction in patients with type 2 diabetes","volume":"14","author":"Guria","year":"2022","journal-title":"Cureus"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Zuo, X., Liu, X., Chen, R., Ou, H., Lai, J., Zhang, Y., and Yan, D. (2019). An in-depth analysis of glycosylated haemoglobin level, body mass index and left ventricular diastolic dysfunction in patients with type 2 diabetes. BMC Endocr. Disord., 19.","DOI":"10.1186\/s12902-019-0419-7"},{"key":"ref_62","first-page":"166","article-title":"Glycemic variability is associated with diastolic dysfunction in patients with type 2 diabetes","volume":"18","author":"Dzhun","year":"2023","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/ehjci\/jew331","article-title":"Diastolic function deterioration in type 2 diabetes mellitus: Predictive factors over a 3-year follow-up","volume":"19","author":"Bergerot","year":"2017","journal-title":"Eur. Heart J.-Cardiovasc. Imaging"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e003643","DOI":"10.1161\/CIRCIMAGING.115.003643","article-title":"Impact of improved glycemic control on cardiac function in type 2 diabetes mellitus","volume":"9","author":"Leung","year":"2016","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/CIRCHEARTFAILURE.114.001990","article-title":"Cardiac structure and function across the glycemic spectrum in elderly men and women free of prevalent heart disease","volume":"8","author":"Skali","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3803\/EnM.2019.34.2.106","article-title":"The role of glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors in reducing cardiovascular events in patients with type 2 diabetes","volume":"34","author":"Kim","year":"2019","journal-title":"Endocrinol. Metab."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.jdiacomp.2016.10.003","article-title":"Exenatide improves diastolic function and attenuates arterial stiffness but does not alter exercise capacity in individuals with type 2 diabetes","volume":"31","author":"Scalzo","year":"2017","journal-title":"J. Diabetes Its Complicat."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure","volume":"6","author":"McMurray","year":"2018","journal-title":"JACC Heart Fail."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"H1760","DOI":"10.1152\/ajpheart.00735.2015","article-title":"The contributions of dipeptidyl peptidase IV to inflammation in heart failure","volume":"310","author":"Zogbi","year":"2016","journal-title":"Am. J. Physiol.-Heart Circ. Physiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12933-021-01228-3","article-title":"A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation, cardiac function, and cardiac metabolism in patients with early-stage type 2 diabetes: The asset study","volume":"20","author":"Hiruma","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_71","unstructured":"Bridges, A., Bistas, K.G., and Jacobs, T.F. (2023, August 17). Exenatide, StatPearls, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK518981\/."},{"key":"ref_72","unstructured":"(2023, August 17). Available online: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"107845","DOI":"10.1016\/j.intimp.2021.107845","article-title":"The role of incretins and incretin-based drugs in autoimmune diseases","volume":"98","author":"Radbakhsh","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41574-021-00621-y","article-title":"Global accessibility of therapeutics for diabetes mellitus","volume":"18","author":"Fralick","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Grigorescu, E.-D., L\u0103c\u0103tu\u0219u, C.-M., Cre\u021bu, I., Floria, M., Onofriescu, A., Ceasovschih, A., Mihai, B.-M., and \u0218orodoc, L. (2021). Self-Reported Satisfaction to Treatment, Quality of Life and General Health of Type 2 Diabetes Patients with Inadequate Glycemic Control from North-Eastern Romania. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18063249"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Grigorescu, E.D., L\u0103c\u0103tu\u0219u, C.M., Floria, M., Cazac, G.D., Onofriescu, A., Ceasovschih, A., Cre\u021bu, I., Mihai, B.M., and \u0218orodoc, L. (2022). Association of Inflammatory and Metabolic Biomarkers with Mitral Annular Calcification in Type 2 Diabetes Patients. J. Pers. Med., 12.","DOI":"10.3390\/jpm12091484"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/17\/2817\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:43:36Z","timestamp":1760129016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/17\/2817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":77,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["diagnostics13172817"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13172817","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2023,8,31]]}}}